Generation of genetically engineered precursor t-cells from human umbilical cord blood using an optimized alpharetroviral vector platform

Molecular Therapy

Volumn 24, Issue 7, 2016, Pages 1216-1226

  Hübner, Juwita ^a   Hoseini, Shahabuddin S ^a   Suerth, Julia D ^a   Hoffmann, Dirk ^a   Maluski, Marcel ^a   Herbst, Jessica ^a   Maul, Holger ^b   Ghosh, Arnab ^c   Eiz Vesper, Britta ^a   Yuan, Qinggong ^a   Ott, Michael ^a   Heuser, Michael ^a   Schambach, Axel ^a   Sauer, Martin G ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Marienkrankenhaus   (Germany)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHARETROVIRAL VECTOR; CD34 ANTIGEN; ENHANCED GREEN FLUORESCENT PROTEIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VECTOR; BIOLOGICAL MARKER; CD123 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE PROTEIN, 75KDA; OUTER MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE SEQUENCE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; ICASPASE 9 GENE; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; MOLECULAR CLONING; MOUSE; MYELOPROLIFERATIVE SARCOMA VIRUS; NONHUMAN; PROCESS OPTIMIZATION; PROMOTER REGION; RETROVIRIDAE; SARCOMA VIRUS; SUICIDE GENE; T LYMPHOCYTE; TARGET CELL; TRANSGENE; UMBILICAL CORD BLOOD; VALIDATION PROCESS; VESICULOVIRUS; VIRUS ENVELOPE; ALPHARETROVIRUS; CELL DIFFERENTIATION; CYTOLOGY; FETUS BLOOD; GENE TRANSFER; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; METABOLISM; PHENOTYPE; PRE T LYMPHOCYTE; REPORTER GENE;

ALPHARETROVIRUS; ANTIGENS, CD34; APOPTOSIS; BACTERIAL OUTER MEMBRANE PROTEINS; BIOMARKERS; CELL DIFFERENTIATION; FETAL BLOOD; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENETIC ENGINEERING; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; PHENOTYPE; PRECURSOR CELLS, T-LYMPHOID; PROMOTER REGIONS, GENETIC; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 84982131040     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.89     Document Type: Article

References (41)

1. Lewis ID, and Verfaillie CM. (2000). Multi-lineage expansion potential of primitive hematopoietic progenitors: superiority of umbilical cord blood compared to mobilized peripheral blood. Exp Hematol 28: 1087-1095.
2. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, et al. (1997). Outcome of cord-blood transplantation from related, and unrelated donors. Eurocord Transplant Group, and the European Blood, and Marrow Transplantation Group. N Engl J Med 337: 373-381.
3. Barker JN, and Wagner JE. (2003). Umbilical-cord blood transplantation for the treatment of cancer. Nat Rev Cancer 3: 526-532.
4. Schmitt TM, and Zúñiga-Pflücker JC. (2002). Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity 17: 749-756.
5. Zakrzewski JL, Kochman AA, Lu SX, Terwey TH, Kim TD, Hubbard VM, et al. (2006). Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat Med 12: 1039-1047.
6. Spits H. (2002). Development of alphabeta T cells in the human thymus. Nat Rev Immunol 2: 760-772.
7. Awong G, Singh J, Mohtashami M, Malm M, La Motte-Mohs RN, Benveniste PM, et al. (2013). Human proT-cells generated in vitro facilitate hematopoietic stem cell-derived T-lymphopoiesis in vivo, and restore thymic architecture. Blood 122: 4210-4219.
8. Zakrzewski JL, Suh D, Markley JC, Smith OM, King C, Goldberg GL, et al. (2008). Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol 26: 453-461.
9. Hoseini SS, Hapke M, Herbst J, Wedekind D, Baumann R, Heinz N, et al. (2015). Inducible T-cell receptor expression in precursor T cells for leukemia control. Leukemia 29: 1530-1542.
10. Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, et al. (2010). Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 363: 355-364.
11. Newrzela S, Cornils K, Li, Z, Baum C, Brugman MH, Hartmann M, et al. (2008). Resistance of mature T cells to oncogene transformation. Blood 112: 2278-2286.
12. Suerth JD, Maetzig T, Brugman MH, Heinz N, Appelt JU, Kaufmann KB, et al. (2012). Alpharetroviral self-inactivating vectors: long-Term transgene expression in murine hematopoietic cells, and low genotoxicity. Mol Ther 20: 1022-1032.
13. Suerth JD, Maetzig T, Galla M, Baum C, and Schambach A. (2010). Self-inactivating alpharetroviral vectors with a split-packaging design. J Virol 84: 6626-6635.
14. Awong G, Herer E, Surh CD, Dick JE, La Motte-Mohs RN, and Zúñiga-Pflücker JC. (2009). Characterization in vitro, and engraftment potential in vivo of human progenitor T cells generated from hematopoietic stem cells. Blood 114: 972-982.
15. Fehse B, Kustikova OS, Bubenheim M, and Baum C. (2004). Pois(s)on-it's a question of dose. Gene Ther 11: 879-881.
16. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
17. Morris E, Hart D, Gao L, Tsallios A, Xue SA, and Stauss H. (2006). Generation of tumor-specific T-cell therapies. Blood reviews 20: 61-69.
18. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, et al. (2003). Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80, and interleukin-15. Nat Med 9: 279-286.
19. Bridgeman JS, Hawkins RE, Hombach AA, Abken H, and Gilham DE. (2010). Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther 10: 77-90.
20. Sadelain M, Brentjens R, and Rivière I. (2013). The basic principles of chimeric antigen receptor design. Cancer Discov 3: 388-398.
21. Porter DL, Roth MS, McGarigle C, Ferrara JL, and Antin JH. (1994). Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330: 100-106.
22. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. (2013). CD19-Targeted T cells rapidly induce molecular remissions in adults with chemotherapyrefractory acute lymphoblastic leukemia. Sci Transl Med 5: 177ra38.
23. Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, et al. (2012). A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-Antigen-receptor, and eliminate expression of endogenous TCR. Blood 119: 5697-5705.
24. De Smedt M, Hoebeke I, and Plum J. (2004). Human bone marrow CD34+ progenitor cells mature to T cells on OP9-DL1 stromal cell line without thymus microenvironment. Blood Cells Mol Dis 33: 227-232.
25. Offner F, Kerre T, De Smedt M, and Plum J. (1999). Bone marrow CD34 cells generate fewer T cells in vitro with increasing age, and following chemotherapy. Br J Haematol 104: 801-808.
26. Schmitt TM, de Pooter RF, Gronski MA, Cho SK, Ohashi PS, and Zúñiga-Pflücker JC. (2004). Induction of T cell development, and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat Immunol 5: 410-417.
27. Snauwaert S, Verstichel G, Bonte S, Goetgeluk G, Vanhee S, Van Caeneghem Y, et al. (2014). In vitro generation of mature naive antigen-specific CD8(+) T cells with a single T-cell receptor by agonist selection. Leukemia 28: 830-841.
28. Patel E, Wang B, Lien L, Wang Y, Yang LJ, Moreb JS, et al. (2009). Diverse T-cell differentiation potentials of human fetal thymus fetal liver cord blood, and adult bone marrow CD34 cells on lentiviral Delta-like-1-modified mouse stromal cells. Immunology 128(1 Suppl): e497-e505.
29. Holland AM, Zakrzewski JL, Tsai JJ, Hanash AM, Dudakov JA, Smith OM, et al. (2012). Extrathymic development of murine T cells after bone marrow transplantation. J Clin Invest 122: 4716-4726.
30. Ikeda Y, Takeuchi Y, Martin F, Cosset FL, Mitrophanous K, and Collins M. (2003). Continuous high-Titer HIV-1 vector production. Nat Biotechnol 21: 569-572.
31. Throm RE, Ouma AA, Zhou S, Chandrasekaran A, Lockey T, Greene M, et al. (2009). Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 113: 5104-5110.
32. Suerth JD, Schambach A, and Baum C. (2012). Genetic modification of lymphocytes by retrovirus-based vectors. Curr Opin Immunol 24: 598-608.
33. Zychlinski D, Schambach A, Modlich U, Maetzig T, Meyer J, Grassman E, et al. (2008). Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 16: 718-725.
34. Zhang F, Thornhill SI, Howe SJ, Ulaganathan M, Schambach A, Sinclair J, et al. (2007). Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element. (UCOE) provide highly reproducible, and stable transgene expression in hematopoietic cells. Blood 110: 1448-1457.
35. Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, et al. (2010). Genomic instability, and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16: 198-204.
36. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365: 1673-1683.
37. La Motte-Mohs RN, Herer E, and Zúñiga-Pflücker JC. (2005). Induction of T-cell development from human cord blood hematopoietic stem cells by Delta-like 1 in vitro. Blood 105: 1431-1439.
38. Gerull S, Beard BC, Peterson LJ, Neff T, and Kiem HP. (2007). In vivo selection, and chemoprotection after drug resistance gene therapy in a nonmyeloablative allogeneic transplantation setting in dogs. Hum Gene Ther 18: 451-456.
39. Sandrin V, Boson B, Salmon P, Gay W, Nègre D, Le Grand R, et al. (2002). Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera, and augmented transduction of primary lymphocytes, and CD34+ cells derived from human, and nonhuman primates. Blood 100: 823-832.
40. Rahman L, Bliskovski V, Kaye FJ, and Zajac-Kaye M. (2004). Evolutionary conservation of a 2-kb intronic sequence flanking a tissue-specific alternative exon in the PTBP2 gene. Genomics 83: 76-84.
41. Pfaffl MW. (2001). A new mathematical model for relative quantification in real-Time RT-PCR. Nucleic Acids Res 29: e45.